Keytruda has beaten Roche’s TIGIT drug candidate at the first interim analysis of a phase 2/3 lung cancer trial, prompting ...

Roche Holding AG will halt a study of an experimental cancer drug after it failed to help patients with advanced forms of non ...

locally advanced unresectable or metastatic non-squamous non-small cell lung cancer (nSq NSCLC), did not meet its primary endpoints of progression-free survival (PFS) at its primary analysis with a ...

A new technology now being offered at Community Regional is helping doctors detect lung cancer far sooner than ever before.

However, evidence indicates that the back is one of the most common sites in the body where people with lung cancer ...

Investigators compared cost-effectiveness of the KRAS inhibitor sotorasib against the taxane docetaxel in the second line for ...

Johnson & Johnson (JNJ) announced that Health Canada has issued a Notice of Compliance for RYBREVANT in combination with ...

One of the other presentations I'll just highlight is that one of our residents at Yale actually had a presentation yesterday ...

For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), amivantamab-lazertinib yields improved progression-free survival compared with osimertinib as first-line treatment.

If you or a loved one are considering volunteering for an ovarian cancer clinical trial, here’s what to know about the ...

On June 12, 2024, the FDA granted traditional approval to selpercatinib for the treatment of for adult and pediatric patients ...

For such a common disease, lung cancer can be hard to spot. In the early stages you probably won't even know you've got a ...